The paper is a one-year retrospective review of the incidence of Clostridium difficile infection in NewYork-Presbyterian/Weill Cornell Medical Center inpatients.
This award is presented annually to members of the Weill Department of Medicine below the rank of professor who perform on outstanding levels in the areas of clinical and/or basic biomedical research.
Patients with the most common type of metastatic pancreatic cancer showed improved results when treated with a combination of an investigational drug, an immunotherapy drug, and chemotherapy.
The study found that ramped-up production of Tph1 helps ILC2s to enter an inflammatory state. This advance may lead to future drugs that could suppress Tph1 in an attempt to alleviate allergic and inflammatory conditions.
The award supports selected faculty during the crucial period of career development, spanning completion of research training through the early years of their first faculty position held at Weill Cornell Medicine.
The study has yielded breakthroughs to help illuminate a growing body of evidence that gut microbial metabolites play a critical role in mucosal immunity and inflammation.
The paper opens a new window on the control of blood glucose levels through the liver via gut microbiome.
The grant will fund critical studies on HPV-related cancers in people living with HIV and will include clinical trials focused on two forms of cancer – oropharyngeal and cervical.
Dr. Lo and colleagues hope that by using adipsin or DUSP26 therapies, patients with type 2 diabetes will be spared from developing beta cell failure and thus spared from insulin injections.
In a collaborative study, Dr. John R. Lee and colleagues revealed a first-of-its-kind discovery showing that the abundance of uropathogens in the gut is associated with future development of UTI.
